本帖最后由 老马 于 2012-1-13 21:20 编辑 6 [- V9 N& B+ i! `
# p& v$ X! P3 ?
爱必妥和阿瓦斯丁的比较
7 O, R' I7 T" L$ `. N! T7 J
% Y9 m% V j* a
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/ M7 q" S! o% m& J1 @- j& X: n+ d$ Z
6 a( ~7 M% d! _2 |* E' h
" ]& ~+ s( N1 C8 ]* q6 U: I
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/3 s% r4 R" `0 h( ~8 [* }
==================================================
Z' L/ e) N: N. M9 c7 eOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
$ z+ b" S; L- E" PPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
2 I T" \7 E/ d! aResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported." c4 O. I( F B+ k+ B
|